Project Details
| Status | Active |
|---|---|
| Effective start/end date | 23/03/21 → 23/03/27 |
Funding
- Boehringer Ingelheim (Germany): A$1,769,698.00
- AstraZeneca (United Kingdom)
-
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D., De Blasio, M. J. & Ritchie, R. H., May 2025, In: Journal of Molecular and Cellular Cardiology. 202, p. 102-115 14 p.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access3 Link opens in a new tab Citations (Scopus) -
A novel chemoreactive calcilytic for the potential treatment of autosomal dominant hypocalcemia
Dangerfield, J., DeBono, A., Keller, A. N., Josephs, T. M., Shackleford, D. M., Gregory, K. J., Leach, K. & Capuano, B., Oct 2025, In: Acta Pharmaceutica Sinica B. 15, 10, p. 5387-5399 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles
Chen, M. Z., Yuen, D., McLeod, V. M., Yong, K. W., Smyth, C. H., Herling, B. R., Payne, T. J., Fabb, S. A., Belousoff, M. J., Algarni, A., Sexton, P. M., Porter, C. J. H., Pouton, C. W. & Johnston, A. P. R., 4 Aug 2025, In: Nature Nanotechnology. 20, p. 1273–1284 21 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access28 Link opens in a new tab Citations (Scopus)